Aurinia Pharmaceuticals I... (AUPH)
Aurinia Pharmaceuticals Statistics
Share Statistics
Aurinia Pharmaceuticals has 137.34M shares outstanding. The number of shares has increased by -3.97% in one year.
Shares Outstanding | 137.34M |
Shares Change (YoY) | -3.97% |
Shares Change (QoQ) | -4.08% |
Owned by Institutions (%) | 40.33% |
Shares Floating | 122.12M |
Failed to Deliver (FTD) Shares | 137.76K |
FTD / Avg. Volume | 9.55% |
Short Selling Information
The latest short interest is 7.48M, so 5.22% of the outstanding shares have been sold short.
Short Interest | 7.48M |
Short % of Shares Out | 5.22% |
Short % of Float | 5.81% |
Short Ratio (days to cover) | 5.5 |
Valuation Ratios
The PE ratio is 223.34 and the forward PE ratio is 14.33. Aurinia Pharmaceuticals's PEG ratio is -2.08.
PE Ratio | 223.34 |
Forward PE | 14.33 |
PS Ratio | 5.46 |
Forward PS | 2.7 |
PB Ratio | 3.4 |
P/FCF Ratio | 29.13 |
PEG Ratio | -2.08 |
Enterprise Valuation
Aurinia Pharmaceuticals has an Enterprise Value (EV) of 1.28B.
EV / Sales | 5.45 |
EV / EBITDA | 40.36 |
EV / EBIT | 28.85 |
EV / FCF | 29.03 |
Financial Position
The company has a current ratio of 4.57, with a Debt / Equity ratio of 0.21.
Current Ratio | 4.57 |
Quick Ratio | 4.17 |
Debt / Equity | 0.21 |
Debt / EBITDA | 2.5 |
Debt / FCF | 1.8 |
Interest Coverage | -0.97 |
Financial Efficiency
Return on Equity is 1.52% and Return on Invested Capital is -0.77%.
Return on Equity | 1.52% |
Return on Assets | 1.04% |
Return on Invested Capital | -0.77% |
Revenue Per Employee | $1.81M |
Profits Per Employee | $44.25K |
Employee Count | 130 |
Asset Turnover | 0.43 |
Inventory Turnover | 0.72 |
Taxes
Income Tax | 1.7M |
Effective Tax Rate | 22.77% |
Stock Price Statistics
The stock price has increased by 57.96% in the last 52 weeks. The beta is 1.22, so Aurinia Pharmaceuticals's price volatility has been higher than the market average.
Beta | 1.22 |
52-Week Price Change | 57.96% |
50-Day Moving Average | 8.11 |
200-Day Moving Average | 7.4 |
Relative Strength Index (RSI) | 45.29 |
Average Volume (20 Days) | 1.44M |
Income Statement
In the last 12 months, Aurinia Pharmaceuticals had revenue of 235.13M and earned 5.75M in profits. Earnings per share was 0.04.
Revenue | 235.13M |
Gross Profit | 206.88M |
Operating Income | -4.69M |
Net Income | 5.75M |
EBITDA | 31.73M |
EBIT | 12.28M |
Earnings Per Share (EPS) | 0.04 |
Balance Sheet
The company has 83.43M in cash and 79.37M in debt, giving a net cash position of 4.06M.
Cash & Cash Equivalents | 83.43M |
Total Debt | 79.37M |
Net Cash | 4.06M |
Retained Earnings | -936.57M |
Total Assets | 550.64M |
Working Capital | 348.83M |
Cash Flow
In the last 12 months, operating cash flow was 44.39M and capital expenditures -281K, giving a free cash flow of 44.11M.
Operating Cash Flow | 44.39M |
Capital Expenditures | -281K |
Free Cash Flow | 44.11M |
FCF Per Share | 0.31 |
Margins
Gross margin is 87.99%, with operating and profit margins of -1.99% and 2.45%.
Gross Margin | 87.99% |
Operating Margin | -1.99% |
Pretax Margin | 3.17% |
Profit Margin | 2.45% |
EBITDA Margin | 13.49% |
EBIT Margin | -1.99% |
FCF Margin | 18.76% |
Dividends & Yields
AUPH does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 0.45% |
FCF Yield | 3.43% |
Analyst Forecast
The average price target for AUPH is $11.5, which is 43% higher than the current price. The consensus rating is "Buy".
Price Target | $11.5 |
Price Target Difference | 43% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Stock Splits
The last stock split was on Oct 23, 2013. It was a backward split with a ratio of 1:50.
Last Split Date | Oct 23, 2013 |
Split Type | backward |
Split Ratio | 1:50 |
Scores
Altman Z-Score | 2.69 |
Piotroski F-Score | 7 |